The corresponding 10-year cancer incidences were 1.84% for normal weight, 2.24% for class 1 obesity, and 2.62% for class 2 obesity. The difference between normal weight and class 2 obesity was 0.78 percentage points, equivalent to approximately 8 additional cancer diagnoses per 1000 individuals over 10 years. That absolute difference provides useful context for the 43% higher adjusted hazard.1
Abdominal Obesity Adds to the Association
Within the class 1 obesity group, participants with abdominal obesity had a 10-year cancer incidence of 2.45%, compared with 2.13% among those without abdominal obesity. Their incidence also exceeded the 2.20% observed in participants with class 2 obesity without abdominal obesity. These findings suggest that BMI alone does not fully capture obesity-associated cancer risk.1
The relative association was stronger in men. Across overweight, class 1 obesity, and class 2 obesity, HRs were 1.13, 1.29, and 1.58 in men, respectively, compared with 1.08, 1.15, and 1.28 in women. These estimates describe differences relative to normal-weight participants within each sex; they should not be interpreted as a direct comparison of overall cancer incidence between men and women.1
The publisher’s study summary identified the strongest associations for thyroid, endometrial, and ovarian cancers. The findings fit within broader evidence linking excess body weight to at least 13 cancer types, including colorectal cancer and multiple myeloma. Proposed mechanisms include chronic inflammation and changes in hormonal signaling, although this cohort did not establish the biological pathways responsible for its findings.1-3
Implications for Pharmacy Practice
For pharmacists, the results provide a basis for discussing weight management as part of long-term preventive care with younger adults. Counseling can place cancer risk alongside the established metabolic consequences of obesity while helping patients access structured lifestyle programs or discuss appropriate obesity treatment with their clinicians.2
The study does not establish that intentional weight loss in early adulthood prevents cancer. Its observational design leaves room for residual confounding, including differences in smoking intensity and duration that smoking-status adjustment does not capture. Findings from a Korean health-screening population also require caution when applied to other populations.1
Current USPSTF guidance recommends colorectal cancer screening beginning at age 45 years for average-risk, asymptomatic adults. Pharmacists can reinforce guideline-based screening while supporting earlier attention to modifiable risk factors.4
REFERENCES1. Jang Y, Kim T, Choi Y, et al. Association between obesity and cancer risk in adults with HIV in Korea. AIDS. 2024;38(9):1386-1394. doi:10.1097/QAD.00000000000039042. Obesity and cancer. CDC. August 28, 2026. Accessed October 28, 2026. https://www.cdc.gov/cancer/risk-factors/obesity.html3. Obesity and cancer. National Cancer Institute. January 28, 2025. Accessed October 28, 2026. https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet4. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238